Silvadazin 25gm Cream

Uses of Silvadazin 25gm Cream

Burn wound infections

How does Silvadazin 25gm Cream work?

It stops the bacteria from producing folic acid, a nutrient required for bacterial multiplication.

Side Effects of Silvadazin 25gm Cream

• Burning
• Irritation
• Itching
• Redness at the application site

Quick Sugegstions:

• Silvadazin 25gm Cream is used for the prevention and treatment of wound infections in patients with second and third-degree burns.
• It should not be used in children and infants without consulting a doctor.
• Don't use the medicine for a prolonged duration and internal wounds.

How to administer Silvadazin 25gm Cream

• Burns: Clean the burn wound and apply the cream over all affected areas to a depth of 3-5mm. Reapply as necessary, at least every 24 hours or more frequently if there is significant exudate.
• Hand Burns: Enclose the whole hand in a clear plastic bag or glove before applying the cream. Change the dressing when excessive exudate accumulates.
• Leg Ulcers/Pressure Sores: Fill the cavity of the ulcer with cream to a depth of at least 3-5mm. Follow with an absorbent pad or gauze dressing and apply pressure bandaging as appropriate. Change dressings daily or every 48 hours for less exudative wounds.

Pharmacology

The antibacterial mechanism of Silver Sulfadiazine involves several steps:

• Structural Changes in Bacterial Cell Membrane: Upon exposure to the drug, the bacterial cell membrane undergoes structural changes, including distortion, enlargement, and weakening of the cell wall membrane. These alterations contribute to a reduction in the viability of susceptible bacterial strains.
• Binding of Silver Moiety to Bacterial Cells: The Silver Sulfadiazine molecule dissociates, and the silver component binds to the bacterial cells. This binding process is believed to occur after the silver moiety penetrates the bacterial cell wall.
• Inhibition of Bacterial Cell Proliferation: Once attached to the bacterial DNA, the silver moiety prevents bacterial cell proliferation. This action disrupts the bacterial replication process, hindering the spread and growth of bacteria.
• Selective Action on Bacterial DNA: The concentration of DNA in mammalian cells is significantly higher than in bacterial cells. The ratio of silver sulfadiazine to bacterial DNA is thought to be sufficiently high to inhibit bacterial division while maintaining a low enough ratio to prevent interference with epithelial cell regeneration.
• Bacteriostatic Action: In addition to its bactericidal effects, the sulfadiazine moiety of Silver Sulfadiazine provides bacteriostatic action against susceptible organisms. This action further contributes to the inhibition of bacterial growth and infection.

Dosage & Administration

Adult Dose

For topical/cutaneous treatment and prophylaxis of infection in severe burns:

• Apply onto the affected area 1-2 times/day.

Child Dose

• <2 months: Contraindicated
• >2 months (1% cream): Apply onto the affected area 1-2 times/day.

Interaction

Drug-Drug Interactions:

1. Anti-diabetics: Silver Sulfadiazine may potentiate the antidiabetic effect of sulphonylureas. Close monitoring of blood glucose levels is advised when using Silver Sulfadiazine concurrently with anti-diabetic medications.
2. Local Anaesthetics: Silver Sulfadiazine may interact with various local anesthetics such as lidocaine, causing potential additive effects on nerve function or skin irritation. Caution is recommended when using these medications together.
3. Antiepileptic Drugs (Phenytoin): Concurrent use of Silver Sulfadiazine with phenytoin, an antiepileptic medication, may potentiate phenytoin's action. Monitoring of phenytoin levels in the blood is advisable in patients receiving both medications.
4. Anti-ulcer Drugs (Cimetidine): Coadministration of cimetidine, an anti-ulcer medication, with Silver Sulfadiazine, may increase the incidence of leukopenia (reduced white blood cell count) in individuals with large-area burns. Close monitoring of blood cell counts is recommended in such cases.
5. Enzymes (Collagenase): Silver Sulfadiazine may potentially inactivate enzymatic debriding agents such as collagenase. Avoid concurrent use of these medications due to the risk of reduced efficacy.

Drug-Food Interaction: No significant interactions between Silver Sulfadiazine and food have been identified or established.

Drug-Disease Interactions: Before initiating treatment with Silver Sulfadiazine, inform your doctor if you have any of the following conditions:

1. Allergic reactions to Silver Sulfadiazine: Patients with a history of hypersensitivity or allergic reactions to Silver Sulfadiazine should avoid its use.
2. Glucose-6-phosphate dehydrogenase deficiency: Individuals with this genetic enzyme deficiency may experience hemolytic reactions when exposed to certain medications, including Silver Sulfadiazine. Caution is advised.
3. Kidney or liver problems: Silver Sulfadiazine should be used with caution in patients with preexisting kidney or liver impairment, as drug clearance may be compromised.
4. Low white blood cell count: Silver Sulfadiazine may cause temporary leukopenia (reduced white blood cell count) in some patients. Monitoring of blood cell counts is recommended in individuals with preexisting low white blood cell counts.

Contraindications

• Hypersensitivity to Silver Sulfadiazine or other components of the cream
• Pregnancy at term, premature infants, or infants during the first months of life
• Impaired hepatic or renal function
• Suspected porphyria

Pregnancy & Lactation

Silver Sulfadiazine is classified as Pregnancy Category B, indicating that animal reproduction studies have not demonstrated a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women. Therefore, the use of Silver Sulfadiazine during pregnancy should only be considered if justified, especially in pregnant women approaching or at term. It is essential to weigh the potential benefits of the medication against the potential risks to the fetus.

Regarding breastfeeding, it is not known whether Silver Sulfadiazine is excreted in human milk. Therefore, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother and the potential risk to the infant.

Precautions & Warnings

Silver Sulfadiazine should be used during pregnancy only if the benefits outweigh the potential risks. It's essential to discuss all risks and benefits with the doctor before using this medicine.

Silver sulfadiazine is not recommended for use in breastfeeding women unless necessary. The decision to continue breastfeeding or discontinue the drug should be made after discussing the risks and benefits with the doctor.

Patients with severe allergies, bronchial asthma, or AIDS should use Silver Sulfadiazine with caution due to the increased risk of severe hypersensitivity reactions. Any unusual symptoms should be reported to the doctor immediately.

There is a risk of crystalluria with the use of SSilver Sulfadiazine, especially in dehydrated patients. Adequate hydration is recommended during treatment to reduce this risk.

Patients with G6PD deficiency should use Silver Sulfadiazine with extreme caution due to the increased risk of worsening their condition.

Silver Sulfadiazine is not recommended for use in patients under 18 years of age.